S. Maiolatesi

发表

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

D. Carucci, D. Doolan, J. Bruder, 2011, PloS one.

Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers

W. Wang, C. Broder, R. Vassell, 2021, medRxiv.

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

S. Chaudhury, T. Richie, L. Garver, 2020, PloS one.

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection

C. Broder, S. Pollett, T. Burgess, 2022, PloS one.

Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers

C. Broder, K. Bishop-Lilly, R. Cer, 2022, Open forum infectious diseases.

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers

C. Broder, J. Powers, A. Snow, 2021, Open forum infectious diseases.

Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers

C. Broder, J. Powers, A. Snow, 2021, medRxiv.

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

S. Chaudhury, A. Lawrie, E. Bergmann-Leitner, 2021, PloS one.

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Edward B. Miller, J. Bruder, T. Richie, 2013, Human vaccines & immunotherapeutics.

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

D. Carucci, Awalludin Sutamihardja, A. J. McCoy, 2013, PloS one.

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers

C. Broder, R. Vassell, C. Weiss, 2022, Emerging infectious diseases.

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

D. Scott, C. Broder, J. Powers, 2021, BMC Infectious Diseases.

A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.

T. Richie, U. Heininger, J. Bonhoeffer, 2013, Vaccine.

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability

C. Broder, S. Anderson, S. Pollett, 2023, Frontiers in immunology.